Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28597
Title: Angiotensin II Infusion in COVID-19: An International, Multicenter, Registry-based Study.
Austin Authors: Neto, Ary Serpa;Landoni, Giovanni;Ostermann, Marlies;Lumlertgul, Nuttha;Forni, Lui;Alvarez-Belon, Lucas;Trapani, Tony;Alliegro, Patricia V;Zacharowski, Kai;Wiedenbeck, Carolin;de Backer, Daniel;Bellomo, Rinaldo 
Affiliation: Intensive Care.
Data Analytics Research and Evaluation (DARE) Centre..
Department of Critical Care, University of Melbourne, Melbourne, Australia..
Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Australia..
Department of Critical Care Medicine, Hospital Israelita Albert Einstein, Sao Paulo, Brazil..
Department of Intensive Care and Anesthesiology, IRCCS San Raffaele Scientific Institute, Milan, Italy..
Vita-Salute San Raffaele University, Milan, Italy..
Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia..
Department of Critical Care, Guys & St Thomas' Foundation Trust, London, United Kingdom..
Department of Intensive Care, Royal Surrey County Hospital NHS Foundation Trust, Surrey, United Kingdom..
Department of Anesthesiology, Intensive Care Medicine & Pain Therapy, University Hospital Frankfurt, Goethe University, Frankfurt, Germany..
Intensive Care Departments, CHIREC Hospitals, Brussels and Braine l'Alleaud-Waterloo, Belgium..
Issue Date: May-2022
Date: 2022-01-21
Publication information: Journal of Medical Virology 2022; 94(5): 2079-2088
Abstract: In order to expand our understanding of the role of angiotensin II (ANGII) in COVID-19, we conducted an international, multicenter registry study to assess the use of ANGII in patients with COVID-19 compared to patients not receiving ANGII. Critically ill adult patients who were diagnosed with COVID-19 and received ANGII were matched with COVID-19 patients not receiving ANGII according to age, respiratory support, history of hypertension, use of angiotensin converting enzyme inhibitors and/or angiotensin II receptor blocker, and date of admission. All outcomes were exploratory in nature and included improvement in oxygenation, duration of organ support and mortality. In one year, 132 patients were included (65 in ANGII group and 67 in the control group), and patients were comparable in baseline characteristics. During the first 12 hours of infusion, patients in the ANGII had a faster decrease in FiO2 and maintained similar mean arterial pressure levels. Hospital mortality was not statistically significantly different between the groups (53.8% vs. 40.3%; p = 0.226). Within the limitations of such a study design, our findings confirm previous observations of a potentially positive effect of ANGII on blood pressure and FiO2 but no effect on patient-centered outcomes. This article is protected by copyright. All rights reserved.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28597
DOI: 10.1002/jmv.27592
ORCID: 0000-0003-1520-9387
0000-0002-1650-8939
Journal: Journal of Medical Virology
PubMed URL: 35029318
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35029318/
Type: Journal Article
Subjects: Biochemical analysis
Coronavirus
Pathogenesis
Research and Analysis Methods
Respiratory tract
SARS coronavirus
Virus classification
Appears in Collections:Journal articles

Show full item record

Page view(s)

34
checked on Nov 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.